Seroatlas · Human Serome Atlas

NOL9

Polynucleotide 5'-hydroxyl-kinase NOL9

Also known as: FLJ23323, Grc3, NET6, NOL9_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q5SY16
Gene: NOL9
Ensembl: ENSG00000162408
Chromosome: 1
Canonical length: 702 aa
Protein class: Metabolic proteins, Predicted intracellular proteins
Subcellular location: Nucleoli,Intermediate filaments

OverviewNCBI Gene

Enables ATP-dependent polydeoxyribonucleotide 5'-hydroxyl-kinase activity. Involved in maturation of 5.8S rRNA. Located in intermediate filament cytoskeleton and nucleolus. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

702 residues, UniProt reviewed canonical sequence.

>Q5SY16|NOL9
     1  MADSGLLLKR GSCRSTWLRV RKARPQLILS RRPRRRLGSL RWCGRRRLRW RLLQAQASGV
    61  DWREGARQVS RAAAARRPNT ATPSPIPSPT PASEPESEPE LESASSCHRP LLIPPVRPVG
   121  PGRALLLLPV EQGFTFSGIC RVTCLYGQVQ VFGFTISQGQ PAQDIFSVYT HSCLSIHALH
   181  YSQPEKSKKE LKREARNLLK SHLNLDDRRW SMQNFSPQCS IVLLEHLKTA TVNFITSYPG
   241  SSYIFVQESP TPQIKPEYLA LRSVGIRREK KRKGLQLTES TLSALEELVN VSCEEVDGCP
   301  VILVCGSQDV GKSTFNRYLI NHLLNSLPCV DYLECDLGQT EFTPPGCISL LNITEPVLGP
   361  PFTHLRTPQK MVYYGKPSCK NNYENYIDIV KYVFSAYKRE SPLIVNTMGW VSDQGLLLLI
   421  DLIRLLSPSH VVQFRSDHSK YMPDLTPQYV DDMDGLYTKS KTKMRNRRFR LAAFADALEF
   481  ADEEKESPVE FTGHKLIGVY TDFAFRITPR NRESHNKILR DLSILSYLSQ LQPPMPKPLS
   541  PLHSLTPYQV PFNAVALRIT HSDVAPTHIL YAVNASWVGL CKIQDDVRGY TNGPILLAQT
   601  PICDCLGFGI CRGIDMEKRL YHILTPVPPE ELRTVNCLLV GAIAIPHCVL KCQRGIEGTV
   661  PYVTTDYNFK LPGASEKIGA REPEEAHKEK PYRRPKFCRK MK

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against NOL9 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.36
Highest tissue expression: 8.4 nTPM

Expression across tissuesHPA

Tissue

spleen: 8.4 nTPM
bone marrow: 7 nTPM
skeletal muscle: 6.6 nTPM
cerebellum: 5.8 nTPM
pancreas: 5.7 nTPM
skin: 5.6 nTPM

Single-cell type

myonuclei: 84 nCPM
erythrocyte progenitors: 49 nCPM
distal convoluted tubule cells: 41 nCPM
megakaryocyte progenitors: 39 nCPM
pancreatic acinar cells: 39 nCPM
somatotrophs: 38 nCPM

Immune cell

memory CD4 T-cell: 4.5 nTPM
naive CD4 T-cell: 4.5 nTPM
naive CD8 T-cell: 3.8 nTPM
naive B-cell: 3.6 nTPM
basophil: 3.5 nTPM
plasmacytoid DC: 3.5 nTPM

Brain region

hippocampal formation: 22 nTPM
cerebral cortex: 20 nTPM
basal ganglia: 19 nTPM
cerebellum: 19 nTPM
hypothalamus: 18 nTPM
amygdala: 18 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.55
gnomAD pLI: 0.01
gnomAD missense Z: 1.55
DepMap mean gene effect: -1.08
DepMap dependency class: common

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

P-loop containing nucleoside triphosphate hydrolase
Clp1, P-loop domain
Clp1/Grc3
mRNA cleavage and polyadenylation factor CLP1 P-loop
NOL9, C-terminal domain
NOL9, N-terminal domain
Polynucleotide 5'-hydroxyl-kinase NOL9, N-terminal domain
NOL9-like, C-terminal domain

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of NOL9 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads NOL9 as an antibody target. Whether an autoantibody or antibody against NOL9 could matter depends on whether native NOL9 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

NOL9 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label NOL9 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...